skip navigation links
National Cancer Institute
Enterprise Vocabulary Services
Box
NCIm Version: 201808 (Browser Version 2.9, using LexEVS 6.5.1)
SearchBox Top
SearchBox Bottom
anastrozole (CUI C0290883) Suggest changes to this concept
Add to Cart

Terms & Properties

Concept Unique Identifier (CUI): C0290883

NCI Thesaurus Code: C1607  (see NCI Thesaurus info)

Semantic Type: Pharmacologic Substance

Semantic Type: Organic Chemical

NCIt Definition: A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure. As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis. In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)

PDQ Definition: A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure. As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis. In estrogen-dependent breast cancers, anastrozole may inhibit tumor growth. Check for active clinical trials using this agent. (NCI Thesaurus)

NCI-GLOSS Definition: An anticancer drug that is used to decrease estrogen production and suppress the growth of tumors that need estrogen to grow. It is a type of nonsteroidal aromatase inhibitor.

Synonyms & Abbreviations: (see Synonym Details)
1,3-Benzenediacetonitrile, alpha,alpha,alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-
120511-73-1
2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-[5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile)
719344
Alpha,alpha,alpha', alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrazole
Anastrozole (substance)
anastrozole [Chemical/Ingredient]
Anastrozole
Anastrozol
ANAS
Arimidex
Astra brand of anastrozole
AstraZeneca brand of anastrozole
ICI D1033
ICI-D1033
Product containing anastrozole (medicinal product)
Product containing anastrozole
ZD-1033
ZD1033
Zeneca brand of anastrozole
Zeneca ZD 1033

External Source Codes: 
NCI Thesaurus Code C1607 (see NCI Thesaurus info)
CAS Registry Number 120511-73-1 (see NLM ChemIDplus info)
FDA UNII Code 2Z07MYW1AZ
NSC Code 719344 (see NCI DTP info)
PDQ Closed Trial Search ID 42540
PDQ Open Trial Search ID 42540 (check for NCI PDQ open clinical trial info)

Other Properties: Property Definitions
Name Value Source
Accepted_Therapeutic_Use_For Hormone Receptor-Positive Early Breast cancer NCI
ACTIVE 1 SNOMEDCT_US
CASE_SIGNIFICANCE_ID 900000000000448009 SNOMEDCT_US
CHARACTERISTIC_TYPE_ID 900000000000011006 SNOMEDCT_US
CHEBI_ID CHEBI:2704 NCI
Chemical_Formula C17H19N5 NCI
Contributing_Source CTRP NCI
Contributing_Source FDA NCI
CTV3ID heC.. SNOMEDCT_US
CTV3ID XUWno SNOMEDCT_US
DATE_LAST_MODIFIED 2016-01-29 PDQ
DEFINITION_STATUS_ID 900000000000074008 SNOMEDCT_US
EFFECTIVE_TIME 20020131 SNOMEDCT_US
EFFECTIVE_TIME 20030131 SNOMEDCT_US
FDA_UNII_CODE 2Z07MYW1AZ DRUGBANK
FDA_UNII_CODE 2Z07MYW1AZ NDFRT
FR 1198 MSH
HM D009570 MSH
HM D014230 MSH
LEVEL Example Part D Eligible Drugs USPMG
LEVEL Ingredient NDFRT
LT TRD MSH
LT TRD MTH
LT TRD PDQ
MDA 19941216 MSH
MESH_DUI C090450 NDFRT
MESH_NAME anastrozole NDFRT
MESH_UI M0238999 NDFRT
MMR 20141031 MSH
MODIFIER_ID 900000000000451002 SNOMEDCT_US
NCI_THESAURUS_CODE C1607 PDQ
NDFRT_KIND DRUG_KIND NDFRT
NDFRT_KIND INGREDIENT_KIND NDFRT
NUI N0000007441 NDFRT
NUI N0000148427 NDFRT
ORIG_STY Drug/agent PDQ
PA D018931 MSH
PA D047072 MSH
PID 6187 PDQ
RN 2Z07MYW1AZ MSH
RR 120511-73-1 MSH
RXAUI 1314586 RXNORM
RXAUI 2067831 RXNORM
RXAUI 3060862 RXNORM
RXAUI 3091174 RXNORM
RXAUI 3092168 RXNORM
RXAUI 3101315 RXNORM
RXAUI 3101316 RXNORM
RXAUI 3258618 RXNORM
RXAUI 3258619 RXNORM
RXAUI 3258620 RXNORM
RXAUI 3273747 RXNORM
RXAUI 679630 RXNORM
RXCUI 262485 RXNORM
RXCUI 84857 RXNORM
RXN_BN_CARDINALITY single RXNORM
SC 1 MSH
SID APRD00016 DRUGBANK
SOS trade name; aromatase inhibitor; structure given in first source MSH
SPL_SET_ID 03586c40-eb32-45c5-beb7-6762a6b78790 MTHSPL
SPL_SET_ID 07ccde5f-e6f2-4e9a-b1de-d5adc047f6bc MTHSPL
SPL_SET_ID 11628cdc-4e3c-4063-ee9f-c51e2386a820 MTHSPL
SPL_SET_ID 1448e72e-dc7f-4618-9b37-a82c59823839 MTHSPL
SPL_SET_ID 188c6fd5-6695-4d8b-af43-61d9c26abfe9 MTHSPL
SPL_SET_ID 19251d0b-279a-49f5-99b2-0e74d7cca479 MTHSPL
SPL_SET_ID 260cfda7-efe0-84b2-7f74-ea83c610c4ef MTHSPL
SPL_SET_ID 35c8037f-2601-4bd3-b423-2f53af7c0be3 MTHSPL
SPL_SET_ID 3cd04ed6-7c5a-4c4a-9955-ee40839dfea0 MTHSPL
SPL_SET_ID 4a23dc55-9877-4b43-ac2c-cd628c0f5038 MTHSPL
SPL_SET_ID 4bd7e768-2d09-44e6-bacb-7390a5bc5dbc MTHSPL
SPL_SET_ID 4f6df9c0-b3a1-4ba0-83b9-ba06c69c2e08 MTHSPL
SPL_SET_ID 4fee8d4c-bb21-4773-b622-87f9a4ff333a MTHSPL
SPL_SET_ID 5ad69fab-7469-419e-9c52-662e07e52c86 MTHSPL
SPL_SET_ID 5d4f90d4-e535-4681-a863-3d774a2064e6 MTHSPL
SPL_SET_ID 5d7d3cfa-af46-48fd-afee-cddf39d2efde MTHSPL
SPL_SET_ID 611e1f43-1442-4cbb-b7eb-b65de15c6c70 MTHSPL
SPL_SET_ID 6128eda4-ad33-4c23-8d93-5192421fd8d0 MTHSPL
SPL_SET_ID 8058e4e3-39c0-435f-b3f7-249ef3bcc933 MTHSPL
SPL_SET_ID 8d8cdd21-2403-4284-bdfc-d56d6e8ab117 MTHSPL
SPL_SET_ID 8e4f7179-81d7-4715-9cc1-babef97fcca0 MTHSPL
SPL_SET_ID 965c4cb1-f6b8-47ac-bf13-c36639aa908f MTHSPL
SPL_SET_ID a96e22b2-eca3-4438-b959-dc5381085d31 MTHSPL
SPL_SET_ID b33520de-f891-43f8-bd04-1b66795d3dd2 MTHSPL
SPL_SET_ID c58c7013-50a0-4734-8a78-38ff20a3e7eb MTHSPL
SPL_SET_ID c7666def-a855-4ca3-a322-603a88a44101 MTHSPL
SPL_SET_ID c7a36fd8-530e-4c63-97d5-0f80fab5880e MTHSPL
SPL_SET_ID ca16f8de-d9a5-4c6c-957b-ae28497b67ac MTHSPL
SPL_SET_ID ca9d4aff-ffdf-4a46-ad20-e47e5886a19e MTHSPL
SPL_SET_ID cc0c084b-a122-736e-c136-c8cffc92f5f4 MTHSPL
SPL_SET_ID d4550afa-977e-426e-814b-705435d2af81 MTHSPL
SPL_SET_ID d4f43676-0746-4765-9689-3f1e3075fa6a MTHSPL
SPL_SET_ID ddc99d79-fb94-4a91-9c39-9dcdb3dd5d5b MTHSPL
SPL_SET_ID dface914-5135-4136-82f4-75429b496a35 MTHSPL
SPL_SET_ID e46ed5b8-83c9-4adb-890f-0fc612371eea MTHSPL
SPL_SET_ID e8e3c487-abdb-40eb-85d7-c798e7961e85 MTHSPL
SPL_SET_ID f40d2bcc-6b44-455c-8c03-001f39bfecd5 MTHSPL
SPL_SET_ID f881ec1a-d330-41d8-b633-143875c06ea4 MTHSPL
SPL_SET_ID fc0a61a2-78b2-46f7-9933-63fed2c1cebc MTHSPL
SPL_SET_ID fc6adb1b-00a2-40d7-ba92-799393fc689d MTHSPL
SRC Breast Cancer Res Treat 1994;30(1):103-11 MSH
SUBSET_MEMBER 900000000000497000~MAPTARGET~heC.. SNOMEDCT_US
SUBSET_MEMBER 900000000000497000~MAPTARGET~XUWno SNOMEDCT_US
SUBSET_MEMBER 900000000000508004~ACCEPTABILITYID~900000000000548007 SNOMEDCT_US
SUBSET_MEMBER 900000000000508004~ACCEPTABILITYID~900000000000549004 SNOMEDCT_US
SUBSET_MEMBER 900000000000509007~ACCEPTABILITYID~900000000000548007 SNOMEDCT_US
SUBSET_MEMBER 900000000000509007~ACCEPTABILITYID~900000000000549004 SNOMEDCT_US
TERMUI T268999 MSH
TERMUI T269000 MSH
TERMUI T269001 MSH
TERMUI T269002 MSH
TERMUI T269003 MSH
TERMUI T269004 MSH
TERMUI T269005 MSH
TERMUI T440982 MSH
TERMUI T622215 MSH
TERMUI T622216 MSH
TERMUI T622217 MSH
TH AU MSH
TH CA MSH
TH DE MSH
TH ES MSH
TH FDA SRS (2015) MSH
TH FR MSH
TH IE MSH
TH INN (19XX) MSH
TH MX MSH
TH NLM (1994) MSH
TH NLM (2001) MSH
TH NLM (2004) MSH
TH NL MSH
TH UK MSH
TH USAN (19XX) MSH
TH US MSH
TYPE_ID 900000000000003001 SNOMEDCT_US
TYPE_ID 900000000000013009 SNOMEDCT_US
VANDF_RECORD 50.416^3610^Active/Master NDFRT
VANDF_RECORD 50.6^3323^Active/Master NDFRT
VUID 4020948 NDFRT

Additional Concept Data:  (none)

URL to Bookmark: https://ncim-stage.nci.nih.gov/ncimbrowser/ConceptReport.jsp?dictionary=NCI Metathesaurus&code=C0290883

Mainbox Bottom